Literature DB >> 20133621

Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland.

Manfred Beleut1, Renuga Devi Rajaram, Marian Caikovski, Ayyakkannu Ayyanan, Davide Germano, Yongwon Choi, Pascal Schneider, Cathrin Brisken.   

Abstract

The mouse mammary gland develops postnatally under the control of female reproductive hormones. Estrogens and progesterone trigger morphogenesis by poorly understood mechanisms acting on a subset of mammary epithelial cells (MECs) that express their cognate receptors, estrogen receptor alpha (ERalpha) and progesterone receptor (PR). Here, we show that in the adult female, progesterone drives proliferation of MECs in two waves. The first, small wave, encompasses PR(+) cells and requires cyclin D1, the second, large wave, comprises mostly PR(-) cells and relies on the tumor necrosis factor (TNF) family member, receptor activator of NF-kappaB-ligand (RANKL). RANKL elicits proliferation by a paracrine mechanism. Ablation of RANKL in the mammary epithelium blocks progesterone-induced morphogenesis, and ectopic expression of RANKL in MECs completely rescues the PR(-/-) phenotype. Systemic administration of RANKL triggers proliferation in the absence of PR signaling, and injection of a RANK signaling inhibitor interferes with progesterone-induced proliferation. Thus, progesterone elicits proliferation by a cell-intrinsic and a, more important, paracrine mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20133621      PMCID: PMC2840294          DOI: 10.1073/pnas.0915148107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  49 in total

1.  IGF-2 is a mediator of prolactin-induced morphogenesis in the breast.

Authors:  Cathrin Brisken; Ayyakkannu Ayyannan; Cuc Nguyen; Anna Heineman; Ferenc Reinhardt; Jian Tan; S K Dey; G Paolo Dotto; Robert A Weinberg; Tian Jan
Journal:  Dev Cell       Date:  2002-12       Impact factor: 12.270

2.  IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.

Authors:  Y Cao; G Bonizzi; T N Seagroves; F R Greten; R Johnson; E V Schmidt; M Karin
Journal:  Cell       Date:  2001-12-14       Impact factor: 41.582

3.  Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation.

Authors:  S Z Haslam; G Shyamala
Journal:  Biochem J       Date:  1979-07-15       Impact factor: 3.857

4.  The signaling domain of the erythropoietin receptor rescues prolactin receptor-mutant mammary epithelium.

Authors:  Cathrin Brisken; Merav Socolovsky; Harvey F Lodish; Robert Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-15       Impact factor: 11.205

5.  Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors.

Authors:  Susan Harless Smith; Michael P Cancro
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

6.  Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase.

Authors:  Ray-Chang Wu; Jun Qin; Yoshihiro Hashimoto; Jiemin Wong; Jianming Xu; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

7.  Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform.

Authors:  Biserka Mulac-Jericevic; John P Lydon; Francesco J DeMayo; Orla M Conneely
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-01       Impact factor: 11.205

8.  Progesterone induction of calcitonin expression in the murine mammary gland.

Authors:  P M Ismail; F J DeMayo; P Amato; J P Lydon
Journal:  J Endocrinol       Date:  2004-02       Impact factor: 4.286

9.  Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography.

Authors:  C W Daniel; G B Silberstein; P Strickland
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

10.  Risk factors for breast cancer according to estrogen and progesterone receptor status.

Authors:  Graham A Colditz; Bernard A Rosner; Wendy Y Chen; Michelle D Holmes; Susan E Hankinson
Journal:  J Natl Cancer Inst       Date:  2004-02-04       Impact factor: 13.506

View more
  145 in total

Review 1.  Wnt signaling in mammary glands: plastic cell fates and combinatorial signaling.

Authors:  Caroline M Alexander; Shruti Goel; Saja A Fakhraldeen; Soyoung Kim
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-10-01       Impact factor: 10.005

2.  Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion.

Authors:  Guenther G Steger; Rupert Bartsch
Journal:  Ther Adv Med Oncol       Date:  2011-09       Impact factor: 8.168

3.  The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.

Authors:  Heba S Omar; Olfat G Shaker; Yasser H Nassar; Samar A Marzouk; Mohamed S ElMarzouky
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

Review 4.  RANKL inhibition: a promising novel strategy for breast cancer treatment.

Authors:  Eva González-Suárez
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

5.  Research resource: progesterone receptor targetome underlying mammary gland branching morphogenesis.

Authors:  Ashlee R Lain; Chad J Creighton; Orla M Conneely
Journal:  Mol Endocrinol       Date:  2013-08-26

6.  Attenuation of Mammary Gland Dysplasia and Feeding Difficulties in Tabby Mice by Fetal Therapy.

Authors:  Mandy Wahlbuhl; Sonia Schuepbach-Mallepell; Christine Kowalczyk-Quintas; Angela Dick; Fabian B Fahlbusch; Pascal Schneider; Holm Schneider
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-06-01       Impact factor: 2.673

7.  Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.

Authors:  Danja Sarink; Helena Schock; Theron Johnson; Kim Overvad; Marianne Holm; Anne Tjønneland; Marie-Christine Boutron-Ruault; Mathilde His; Marina Kvaskoff; Heiner Boeing; Pagona Lagiou; Eleni-Maria Papatesta; Antonia Trichopoulou; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Carlotta Sacerdote; H B As Bueno-de-Mesquita; Carla H van Gils; Petra H Peeters; Elisabete Weiderpass; Antonio Agudo; Maria-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; Kay Tee Khaw; Ruth Travis; Laure Dossus; Mark Gunter; Sabina Rinaldi; Melissa Merritt; Elio Riboli; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Prev Res (Phila)       Date:  2017-07-12

Review 8.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

Review 9.  Changing concepts: Menopausal hormone therapy and breast cancer.

Authors:  Rowan T Chlebowski; Garnet L Anderson
Journal:  J Natl Cancer Inst       Date:  2012-03-16       Impact factor: 13.506

Review 10.  Mammary gland development.

Authors:  Hector Macias; Lindsay Hinck
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2012 Jul-Aug       Impact factor: 5.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.